These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12421218)

  • 1. Acquired and transient RBC CD55 deficiency (Inab phenotype) and anti-IFC.
    Matthes T; Tullen E; Poole J; Banks J; Nagy M; Stelling MJ; Boehlen F; Michel M; Beris P; Hustinx H; Crew V; Daniels G
    Transfusion; 2002 Nov; 42(11):1448-57. PubMed ID: 12421218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case report and literature review: transient Inab phenotype and an agglutinating anti-IFC in a patient with a gastrointestinal problem.
    Yazer MH; Judd WJ; Davenport RD; Dake LR; Lomas-Francis C; Hue-Roye K; Powell V; Reid M
    Transfusion; 2006 Sep; 46(9):1537-42. PubMed ID: 16965581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decay-accelerating factor (CD55) deficiency phenotypes in Japanese.
    Daniels GL; Green CA; Mallinson G; Okubo Y; Hori Y; Kataoka A; Kaihara M
    Transfus Med; 1998 Jun; 8(2):141-7. PubMed ID: 9675792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel molecular basis of an Inab phenotype.
    Hue-Roye K; Powell VI; Patel G; Lane D; Maguire M; Chung A; Reid ME
    Immunohematology; 2005; 21(2):53-5. PubMed ID: 15954804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Inab phenotype: characterization of the membrane protein and complement regulatory defect.
    Telen MJ; Green AM
    Blood; 1989 Jul; 74(1):437-41. PubMed ID: 2473800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical studies on red blood cells from a patient with the Inab phenotype (decay-accelerating factor deficiency).
    Reid ME; Mallinson G; Sim RB; Poole J; Pausch V; Merry AH; Liew YW; Tanner MJ
    Blood; 1991 Dec; 78(12):3291-7. PubMed ID: 1720702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF.
    Telen MJ; Hall SE; Green AM; Moulds JJ; Rosse WF
    J Exp Med; 1988 Jun; 167(6):1993-8. PubMed ID: 2455016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis of reduced or absent expression of decay-accelerating factor in Cromer blood group phenotypes.
    Lublin DM; Mallinson G; Poole J; Reid ME; Thompson ES; Ferdman BR; Telen MJ; Anstee DJ; Tanner MJ
    Blood; 1994 Aug; 84(4):1276-82. PubMed ID: 7519480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of CD55- and/or CD59-deficient red cell populations in patients with lymphoproliferative syndromes.
    Meletis J; Terpos E; Samarkos M; Meletis C; Apostolidou E; Komninaka V; Korovesis K; Mavrogianni D; Boutsis D; Variami E; Viniou N; Konstantopoulos K; Loukopoulos D
    Hematol J; 2001; 2(1):33-7. PubMed ID: 11920231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the expression of glycosylphosphatidylinositol anchored proteins on platelets from patients with paroxysmal nocturnal hemoglobinuria.
    Maciejewski JP; Young NS; Yu M; Anderson SM; Sloand EM
    Thromb Res; 1996 Sep; 83(6):433-47. PubMed ID: 8885138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UMC, another Cromer-related blood group antigen.
    Daniels GL; Okubo Y; Yamaguchi H; Seno T; Ikuta M
    Transfusion; 1989; 29(9):794-7. PubMed ID: 2480010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement sensitivity of erythrocytes in a patient with inherited complete deficiency of CD59 or with the Inab phenotype.
    Shichishima T; Saitoh Y; Terasawa T; Noji H; Kai T; Maruyama Y
    Br J Haematol; 1999 Feb; 104(2):303-6. PubMed ID: 10050712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Cromer blood group system: a review.
    Storry JR; Reid ME; Yazer MH
    Immunohematology; 2010; 26(3):109-18. PubMed ID: 21214297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of the survival of paroxysmal nocturnal hemoglobinuria red cells through the immunophenotyping of reticulocytes.
    Navenot JM; Muller JY; Blanchard D
    Transfusion; 1998 Apr; 38(4):337-42. PubMed ID: 9595015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protease-modified erythrocytes: CD55 and CD59 deficient PNH-like cells.
    Yuan FF; Bryant JA; Fletcher A
    Immunol Cell Biol; 1995 Feb; 73(1):66-72. PubMed ID: 7539403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3D analysis of CROMER (DAF) and a new antigen CRAG.
    Floch A; Vege S; Hue-Roye K; Hamilton JR; Williams LA; Choate J; Lomas-Francis C; Westhoff CM
    Blood Transfus; 2022 Nov; 20(6):483-488. PubMed ID: 35175190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cromer-related antigens--blood group determinants on decay-accelerating factor.
    Daniels G
    Vox Sang; 1989; 56(4):205-11. PubMed ID: 2474898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new blood group antigen is defined by anti-CD59, detected in a CD59-deficient patient.
    Anliker M; von Zabern I; Höchsmann B; Kyrieleis H; Dohna-Schwake C; Flegel WA; Schrezenmeier H; Weinstock C
    Transfusion; 2014 Jul; 54(7):1817-22. PubMed ID: 24383981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitive and accurate identification of PNH clones based on ICCS/ESCCA PNH Consensus Guidelines-A summary.
    Illingworth AJ; Marinov I; Sutherland DR
    Int J Lab Hematol; 2019 May; 41 Suppl 1():73-81. PubMed ID: 31069981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel form of congenital dyserythropoietic anemia associated with deficiency of erythroid CD44 and a unique blood group phenotype [In(a-b-), Co(a-b-)].
    Parsons SF; Jones J; Anstee DJ; Judson PA; Gardner B; Wiener E; Poole J; Illum N; Wickramasinghe SN
    Blood; 1994 Feb; 83(3):860-8. PubMed ID: 7507739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.